Abstract 516: Integrated genomic and transcriptional profiling of patient-derived ovarian cancers reveals HRD-associated features and in vivo response to PARP inhibition.

Abstract Introduction: Homologous recombination deficiency (HRD) and BRCA1/2 alterations are key biomarkers for PARP inhibitor sensitivity in ovarian cancer. Transcriptional features such as RB1 expression may further refine biologic subgroups and therapeutic hypotheses. We performed integrated DNA/RNA profiling of FFPE ovarian tumors to characterize histologic distribution, genomic alterations, genomic instability score (GIS), RB1 expression, and in vivo olaparib response in selected HRD-positive models. Methods: Thirty-two patient-derived FFPE ovarian tumor blocks were prepared, and H85% compared to untreated controls. Conclusions: Overall, these findings suggest a meaningful correlation between genomic HRD status and in vivo therapeutic response, supporting the translational relevance of integrated profiling and the use of patient-derived models for preclinical investigations. Citation Format: Kyle C. Strickland, Sheri Barnes, Zachary D. Wallen, Michelle F. Green, Laine V. Morris, Paul DePietro, Kobina A. Amoah, Jennifer B. Jackson, Pratheesh Sathyan, Taylor J. Jensen, Brian Caveney, Eric A. Severson, Rebecca A. Previs, Shakti Ramkissoon, Scott C. Wise. Integrated genomic and transcriptional profiling of patient-derived ovarian cancers reveals HRD-associated features and in vivo response to PARP inhibition abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 516.